Cancer Research Consortium ImmunoTransporter

The consortium´s objective is to develop, improve and optimize immunomodulatory concepts and to overcome their current limitations.

Funding period:

1.11.2014 - 31.10.2017

01.11.2017 - 30.06.2018

Project description:

The consortium´s objective is to develop, improve and optimize immunomodulatory concepts and to overcome their current limitations. The consortium partners will jointly develop methods to achieve tumor-specific activation of a patient's immune system to make it recognize, target and fight cancer. With a novel class of effector molecules and new tailored drug delivery strategies, the consortium strives for increased efficacy and improved tolerability of cancer immunotherapies. Based on the preclinical results, the novel approach shall eventually be translated into clinical trials.

Presseinformation 2015

This image showsRoland Kontermann
Prof. Dr.

Roland Kontermann

Deputy Head of the Institute (Biomedical Engineering)

To the top of the page